# Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)

Study · id `cardio:ct-nct05203224` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05203224](<https://clinicaltrials.gov/study/NCT05203224>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05203224

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 330 participants.

## Technical summary

Registry record NCT05203224. Allocation not applicable; no masking; primary purpose treatment. Start 2022-02-18 (actual); primary completion 2025-11-24 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 330 participants (enrolled count; ClinicalTrials.gov record NCT05203224, source copy `cardio:ctgov-nct05203224-2026-05-06`, retrieved 2026-10-26)
- Started: 2022-02-18 (actual) (ClinicalTrials.gov record NCT05203224, source copy `cardio:ctgov-nct05203224-2026-05-06`, retrieved 2026-10-26)
- Primary completion: 2025-11-24 (actual) (ClinicalTrials.gov record NCT05203224, source copy `cardio:ctgov-nct05203224-2026-05-06`, retrieved 2026-10-26)
- Completion: 2026-02-25 (actual) (ClinicalTrials.gov record NCT05203224, source copy `cardio:ctgov-nct05203224-2026-05-06`, retrieved 2026-10-26)
- Countries: Australia (ClinicalTrials.gov record NCT05203224, source copy `cardio:ctgov-nct05203224-2026-05-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05203224-2026-05-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)
- Condition: Ischemic Stroke
- Intervention (Drug): Dornase Alfa
- Lead sponsor: University of Melbourne
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: University of Melbourne (`cardio:org-university-of-melbourne`)

## Provenance

Content hash: c11133c70b2a0b1ad9ab5cf40403e013149193477bb286e3d7353d860b18ec03
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
